Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia

Article Abstract:

Treatment with famciclovir may significantly reduce the pain and recovery time for patients with herpes zoster (shingles). Shingles is a painful viral infection that results in surface skin sores that follow a major underlying nerve. Researchers divided 419 patients with shingles into three treatment groups. One group took three 500 milligram doses of famciclovir a day, one group took three 750 milligram doses a day, and the third group took a placebo. Pain resolved up to 2.6 times faster in the two groups receiving famciclovir as compared to those taking placebo. This corresponded to an approximate two-month reduction in recovery time. Both groups given famciclovir reported similar results. Patients tolerated the drug well. The only side effects reported were headache and nausea.

Author: Tyring, Stephen, Jones, Terry, Barbarash, Rick A., Nahlik, James E., Cunningham, Anthony, Marley, John, Heng, Madalene, Rea, Ted, Boon, Ron, Saltzman, Robin
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1995
Shingles (Disease), Herpes zoster

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial

Article Abstract:

Famciclovir appears to significantly reduce the symptoms and virus levels associated with herpes simplex virus (HSV) infections among HIV-positive patients. Daily HSV levels in oral and genital tissue areas and patient-reported symptoms were compared for 48 HIV- and HSV-positive patients during eight weeks of famciclovir treatment and eight weeks of placebo treatment. The percentage of days with HSV-positive samples was 9.7% while taking placebo but 1.3% while taking famciclovir. Nearly 14% more patients reported viral symptoms while taking placebo compared to during famciclovir treatment.

Author: Corey, Lawrence, Zeh, Judith, Koelle, David M., Schacker, Timothy, Boon, Ron, Saltzman, Robin, Barnum, Gail, Hu, Hui-lin, Shaughnessy, Mary
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1998
Care and treatment, Evaluation, HIV patients, Herpes simplex, Famciclovir

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Clinical Reactivation of Genital Herpes Simplex Virus Infection Decreases in Frequency over Time

Article Abstract:

Herpes simplex virus type 2 infection is a chronic remitting illness, but over time, a majority of patients report a significant reduction in the frequency of outbreaks. A 14-month or more observation was made of 664 patients with genital herpes. The patients were grouped according to their having initial or recurrent HSV-1 or HSV-2 infection. The recurrent outbreaks reported by the patients as well as those observed were recorded in a database and an analysis made of the more than 12,000 recurrences. A definite decrease in frequency was noted.

Author: Corey, Lawrence, Zeh, Judith, Benedetti, Jacqucline K.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1999
Development and progression, Herpes genitalis, Genital herpes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy
Similar abstracts:
  • Abstracts: Inflammatory bowel disease. Infliximab for the treatment of fistulas in patients with Crohn's disease. A short-term study of chimeric monoclonal antibody to cA2 to tumor necrosis factor alpha for Crohn's disease
  • Abstracts: Risk factors and clinical presentation of acute primary HIV infection in India. Acute primary HIV infection
  • Abstracts: A model to standardise mortality of severely malnourished children using nutritional status on admission to therapeutic feeding centres
  • Abstracts: Help wanted. From bad to good to great: companies buckle down and turn around their safety records. Companies can use case data to help prevent injuries
  • Abstracts: Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. Elevated CD8+DR+ lymphocytes in HIV-exposed infants with early positive HIV cultures: a possible early marker of intrauterine transmission
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.